Author(s):
Mubarak Ali R. Sayyed, Prashant A. Patil, Sandip Dhumal, Dilip R. Birari, Leena N. Patil
Email(s):
leena.patil@sandipuniversity.edu.in
DOI:
10.52711/0974-360X.2025.00540 
Address:
Mubarak Ali R. Sayyed1, Prashant A. Patil4, Sandip Dhumal5, Dilip R. Birari3, Leena N. Patil2*
1,4,5Research Scholar, Department of Chemistry, School of Science, Sandip University, Nashik, Maharashtra, India 422213.
2Assistant Professor, Department of Chemistry, School of Science, Sandip University, Nashik, Maharashtra, India 422213.
3Department of Process Research and Development, Megafine Pharma (P) Ltd., 201, Lakhmapure, Dindori, Nashik, Maharashtra, India 422 202.
*Corresponding Author
Published In:
Volume - 18,
Issue - 8,
Year - 2025
ABSTRACT:
Manufacturing process reported for the synthesis of Lurasidone hydrochloride are uneconomical, inefficient and practically difficult to operate at industrial scale due to their incapability to control process related and isomeric impurities, more no of synthesis steps, high temperature reaction, huge solvent volume and chromatographic purification makes the process uneconomical, hence need develop cost effective and efficient process for the synthesis of lurasidone hydrochloride. Lurasidone has six chiral centres, and it is necessary to quantify the concentration level of each isomer and specify limits for all isomeric components, impurities, and contaminants for effective application of drugs proposed for intended use. The present work explains about the lurasidone hydrochloride process free from optical isomers and focused on the root of formation of different isomers. Control strategy designed for KRM, KSM, intermediate and finished API. This work also explains the effectiveness of proposed control strategy from laboratory to commercial scale
Cite this article:
Mubarak Ali R. Sayyed, Prashant A. Patil, Sandip Dhumal, Dilip R. Birari, Leena N. Patil. Practical and Cost-Effective Process for the Synthesis of Lurasidone Hydrochloride, An-Antipsychotic Drug Through an Efficient Control of Stereo Isomeric Impurities. Research Journal Pharmacy and Technology. 2025;18(8):3749-0. doi: 10.52711/0974-360X.2025.00540
Cite(Electronic):
Mubarak Ali R. Sayyed, Prashant A. Patil, Sandip Dhumal, Dilip R. Birari, Leena N. Patil. Practical and Cost-Effective Process for the Synthesis of Lurasidone Hydrochloride, An-Antipsychotic Drug Through an Efficient Control of Stereo Isomeric Impurities. Research Journal Pharmacy and Technology. 2025;18(8):3749-0. doi: 10.52711/0974-360X.2025.00540 Available on: https://www.rjptonline.org/AbstractView.aspx?PID=2025-18-8-43
REFERENCES:
1. Murray R, B. D. Harper's Illustrated Biochemistry. New York: New York Lange Medical Books/ McGraw-Hill Medical Publishing Division. 2012
2. Riley, T. N., DeRuiter, J., Ravis, W. R., and Clark, R. C. Isomerism. Encyclopedia of Pharmaceutical Technology. 2006
3. Katzung, B. G., Masters, S. B., and Travor, A. J. Basic and Clinical Pharmacology. (12, Ed.) Noida, India: Tata Macgraw- Hill. 2009
4. Chhabra, N., Aseri,, M. L., and Padmanabhan, D. A review of drug isomerism and its significance. Int J Appl Basic Med Res. 2013; 16(8). doi:DOI: 10.4103/2229-516X.112233
5. Davis,, N. M., and Teng, W. X. Importance of chirality in drug therapy and pharmacy practice. (1, Ed.) Advances in Pharmacy. 2003; 3: 242-252.
6. Solanki,, P. V., Babu, S., and Mathad, V. T. A Facile Approach for the Synthesis of Highly Pure Immunomodulator DrugsLeflunomide and Teriflunomide: A Robust Strategy to Control Impurities. (3, Ed.) World Journal of Pharmaceutical Sciences. 2015; 11: 2265-2272.
7. Research, C. f. (5/1/1992). Development of New Stereoisomeric Drugs. U.S.Food and Drud Administarion. Retrieved from https://www.fda.gov/regulatory-information/search-fda-guidance-documents/development-new-stereoisomeric-drugs
8. Zhang, H., Wang, H., Zhu, X., Yuana, Z., and Jianga, H. (). Lurasidone Hydrochloride. Crystallographic Communications, 2012; 68: 1357. doi:https://doi.org/10.1107/S1600536812012883
9. N, G. Chemistry Course Companion for the IB Diploma Programme. London: Oxford University Press. 2007
10. Swarbrick, J. Encyclopedia of Pharmaceutical Technology. 2007; 6(3). doi:https://doi.org/10.1201/b19309
11. Murray, R. K., Granner, D. K., Mayes, P. A., and Rodwell., V. W. Harper’s Biochemistry. Lange Medical Publications
12. McConathy, J., and Owens, M. J. Stereochemistry in Drug Action. 2003; 5. doi: doi: 10.4088/pcc.v05n0202
13. Francis, T. Introduction to Theoretical Stereochemistry. Routledge is an imprint of Taylor and Francis, an Informa Company. 1991
14. Ravi Ganesh, K., Pachore, S. S., Pratap, T. V., and Umesh, K. An Enantioselective Synthesis of ((1 R,2 R)-Cyclohexane-1,2-diyl)bis(methylene)dimethanesulfonate, a Lurasidone Hydrochloride Intermediate. Synthetic Communications. 2015; 43(23). doi: DOI:10.1080/00397911.2015.1074695
15. Filak, L. K., Kalinowski, D. S., Bauer, T. J., and Richardson, D. R. Effect of the Piperazine Unit and Metal-Binding Site Position on the Solubility and Anti-Proliferative Activity of Ruthenium(II)- and Osmium(II)- Arene Complexes of Isomeric Indolo[3,2-c]quinoline—Piperazine Hybrids. Inorganic Chemistry. 2014; 53(13): 6934–6943. doi:https://doi.org/10.1021/ic500825j
16. Ishiyama, T., Tokuda,, K., Ishibashi,, T., Ito, A., Toma, S., and Ohno, Y. Lurasidone (SM-13496), a novel atypical antipsychotic drug, reverses MK-801-induced impairment of learning and memory in the rat passive-avoidance test. Eur J Pharmacol. 2007 doi: 10.1016/j.ejphar.2007.06.058
17. American Society of Health-System Pharmacists. (2019, March). Lurasidone Hydrochloride Monograpg for professional. Drugs.Com
18. [Assignee: Sumitomo Pharmaceuticals] Ikutaro, S., Masayuki, M., Norihiko, T., and Mayumi, Y. Osaka, Japan Patent No. US5532372
19. Mapi Pharma ]Ehud, M., Mizhiritskii, M., Tchilibon, S., and Rubnov, S. (2012). Patent No. WO2013014665
20. Pharmaceutical, T., and [Inventors: Chen Wei, P. Y. (2011). Patent No. CN102731512B
21. Sumitomo Naugatuck. Inventors: Minematsu Hiroyuki, S. T. (2003). Japan Patent No. JP4219696B2
22. Ranbaxy Laboratories limited. Inventors: Jaychanra Suresh Babu, Gahlot Udaibhan Singh, Singh Tarun Kumar, Khanduri Chandra Has (2013). India Patent No. WO2014037886.
23. Edmond Pharma. Inventors: Matteo Zacche', N. ( Fulvio Gerli, P. D., and Pierandrea Gatti, S. G. (2013). US Patent No. US8853395B2